Article

Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Nynne Nyboe Andersen, Tine Jess, Department of Epidemiology Research, Statens Serum Institut, DK-2300 Copenhagen, Denmark.
World Journal of Gastroenterology (Impact Factor: 2.43). 11/2013; 19(43):7561-8. DOI: 10.3748/wjg.v19.i43.7561
Source: PubMed

ABSTRACT The association between inflammatory bowel disease (IBD) and colorectal cancer (CRC) has been acknowledged for almost a century and is assumedly promoted by a chronic inflammation-driven carcinogenic process in the intestine in combination with a genetic predisposition. The magnitude of the risk of CRC in IBD remains a continuing subject of debate. The early, high risk estimates for CRC in IBD were most likely overestimated due to selected patient populations originating from tertiary referral centers with a disproportional high percentage of patients with severe disease. Later population-based studies calculating risk estimates from a broad spectrum of IBD patients have found the risk to be significantly lower. At present, there is evidence that IBD patients with longstanding and extensive disease with uncontrolled inflammation are those at increased risk. Additional, other recognized risk factors include early age at onset, family history of CRC, and concomitant primary sclerosing cholangitis. A significant amount of effort is put into identifying potential preventive factors of CRC in IBD, including surveillance programs and chemopreventive agents but the individual effect of these remains uncertain. Interestingly, recent studies have reported a decline in risk of CRC over time. Surveillance programs and the new treatment strategies, particular biological treatment might be part of the reason for the observed decline in risk of CRC in IBD over time but future studies will have investigate this assumption.

0 Bookmarks
 · 
44 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been proposed that effective disease control through abrogation of inflammation in IBD may also reduce CRC risk in these individual patients. This article summarizes the potential for medical therapy to reduce the risk of CRC via primary and secondary prevention, and offers practical ways in which a goal of mucosal improvement or healing may be incorporated into clinical practice.
    Gastrointestinal Endoscopy Clinics of North America 07/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neoplasia complicating ulcerative colitis (UC-neoplasia) is a problem that is poorly addressed by present surveillance techniques. The association of greater than 300 single nucleotide polymorphisms (SNPs) with inflammatory bowel disease (IBD) suggests the possibility that certain genetic polymorphisms might identify patients with UC destined for malignant degeneration. This present study tested the hypothesis that presently known IBD-associated SNPs may correlate with UC-neoplasia.
    Surgery 03/2014; · 3.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ulcerative colitis (UC) is a condition at increased risk for colorectal carcinoma (CRC) development. Nowa- days, screening and follow-up programs are routinely performed worldwide to promote the early detection of CRCs in subjects with well known risk factors (extent, duration and severity of the disorder). The diffusion of these procedures is presumably the main reason for the marked reduction of cancer incidence and mortal- ity in the course of UC. In addition, chemoprevention has been widely investigated and developed in many medical fields, and aspirin has shown a preventive ef- fect against CRC, while mesalazine has been strongly invoked as a potential chemopreventive agent inUC. However, available studies show some limitations due to the obvious ethical implications of drug withdrawal in UC in order to design a control group. The estrogen receptors (ER) alpha/beta balance seems to have a relevant influence on colorectal carcinogenesis and ER beta appears to parallel apoptosis, and hence an anti- carcinogenic effect. Phytoestrogens are compounds acting as ER beta agonists and have shown a promising chemopreventive effect on sporadic as well as geneti- cally inherited CRC. There is evidence suggesting a role for ERs in UC-related carcinogenesis. In this per- spective, since these substances can be considered as dietary supplements and are completely free from side effects, phytoestrogens could be an interesting option for CRC prevention, even when the disease is a con- sequence of long-term chronic inflammation, as in the course of UC. Further studies of their effects are war- ranted in both the basic research and clinical fields.
    World Journal of Gastroenterology 09/2014; 20(33):11496-11504. · 2.43 Impact Factor